Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong Si Wu Tang Granules, an innovative Category 3.1 traditional Chinese medicine developed by its subsidiary Hebei Wanbang Folon Pharmaceutical.

The formulation—sourced from the Qing-dynasty prescription “Tao Hong Si Wu Decoction”—is intended to treat blood-deficiency and blood-stasis syndromes, addressing symptoms such as irregular menstruation, heavy menstrual flow with clots, and abdominal pain. Group R&D expenditure on the project totaled RMB6.96 million as of April 2026.

Market landscape data show only two comparable Tao Hong Si Wu Tang Granule products have received Chinese approval to date (April 2025 and April 2026). Sales figures for 2025 are not yet available from IQVIA CHPA, leaving commercial benchmarks limited.

The granules must still pass GMP compliance inspection and obtain final marketing authorization before production can commence. Management indicated that the filing acceptance alone will not materially affect the Group’s current financial results, and future sales performance will depend on demand, competitive dynamics, and channel penetration.